Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Waltham, Massachusetts
- Most recent report
- 10-Q, filed Aug 6, 2026
- Incorporated
- Delaware
- Filings on record
- 813 filings
- On EDGAR
- CIK 1590750
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 54
News 8 of 177
- 8-K Quarterly results Aug 6, 2026
- 8-K Other events Jun 29, 2026
- 8-K Shareholder vote results Jun 3, 2026
- 8-K Current report on a material event May 28, 2026
- 8-K Significant contract May 26, 2026
- 8-K Significant contract May 11, 2026
- 8-K Current report on a material event May 5, 2026
- 8-K Quarterly results May 5, 2026
Prospectuses and Registrations 8 of 80
- 424B5 Prospectus supplement for an offering May 8, 2026
- 424B5 Prospectus supplement for an offering May 8, 2026
- FWP Free writing prospectus May 7, 2026
- FWP Free writing prospectus May 7, 2026
- 424B5 Prospectus supplement for an offering May 6, 2026
- 424B5 Prospectus supplement for an offering May 6, 2026
- FWP Free writing prospectus May 5, 2026
- S-8 Registration statement for an employee plan Feb 26, 2026
Proxies 8 of 28
- DEFA14A Extra proxy material Apr 17, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 17, 2026
- DEFA14A Extra proxy material Apr 25, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 25, 2025
- DEFA14A Extra proxy material Jun 10, 2024
- DEFA14A Extra proxy material Apr 26, 2024
- DEF 14A Proxy statement for a shareholder vote Apr 26, 2024
- DEFA14A Extra proxy material Apr 28, 2023
Ownership 8 of 389
- 144 Notice of a proposed sale of restricted stock Aug 19, 2026
- 4 Insider reported a trade Aug 18, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- SCHEDULE 13G Large holder reported a passive stake Aug 14, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- SCHEDULE 13G Large holder reported a passive stake Aug 7, 2026
- 4 Insider reported a trade Jul 2, 2026
Other 8 of 85
- 305B2 May 7, 2026
- ARS Annual report sent to shareholders Apr 17, 2026
- ARS Annual report sent to shareholders Apr 25, 2025
- ARS Annual report sent to shareholders Apr 26, 2024
- ARS Annual report sent to shareholders Apr 28, 2023
- EFFECT Notice that a registration became effective Nov 17, 2021
- CORRESP Reply to SEC staff Nov 15, 2021
- UPLOAD Comment letter from SEC staff Nov 10, 2021
Everything here comes from Viridian Therapeutics, Inc.\DE's own filings on SEC EDGAR. The filing list is rechecked every hour.